Drug Precursors

European Parliament Draft Report on EU Drug Precursors Monitoring and Control Regulation

European Parliament committees have issued a joint draft report setting Parliament’s first-reading position on the proposed EU regulation to tighten monitoring and control of drug precursors, extending obligations to non-scheduled substances, online marketplaces, and high-risk category 2 precursors. This non-binding step signals likely future requirements for chemical and pharmaceutical supply chains around enhanced traceability, electronic reporting, and coordinated enforcement against emerging precursor threats.

23 May 2026, 08:58europarl.europa.euEuropean Union

DEA Final Rule Authorizes Supervisory Diversion and Intelligence Officials to Sign Administrative Subpoenas

DOJ has issued a final rule authorizing DEA Supervisory Diversion Investigators, Field Intelligence Managers, and Intelligence Group Supervisors to sign and issue administrative subpoenas under the Controlled Substances Act, effective upon Federal Register publication in May 2026. This internal delegation increases DEA’s operational capacity to compel records from registrants and precursor handlers, modestly heightening enforcement reach and investigative touchpoints for companies in controlled-substance supply chains.

22 May 2026, 16:46public-inspection.federalregister.govUnited States

Argentina Ministry Of Security Resolution MSEG No. 424 Updates RENPRE Administrative Procedures Manual

On 08 May 2026 Argentina’s Ministry of Security published Resolution MSEG No. 424 updating the administrative procedures manual for the National Register of Chemical Precursors (RENPre). This signals adjustments to how obligations for registered precursor operators are administered, so companies handling listed chemical precursors in Argentina should review the updated manual and verify any impact on their registration and compliance processes.

11 May 2026, 11:40cda.org.arArgentina

Canada Temporarily Adds R 29676, Spirochlorphine and Spirobrorphine to Schedule V of the Controlled Drugs and Substances Act (SOR/2026-71)

Canada has temporarily added synthetic opioids spirochlorphine and spirobrorphine and the precursor R 29676 to Schedule V of the Controlled Drugs and Substances Act from 5 June 2026 to 4 June 2027 via Order SOR/2026-71. This one-year control brings these substances under Health Canada’s controlled-substance and Class A precursor licensing regimes, tightening authorisation and permitting requirements for laboratories, reference standard suppliers and other handlers while signalling potential longer-term scheduling.

8 May 2026, 11:08gazette.gc.caCanada

California Senate Advances SB 1306 on Gamma‑Butyrolactone (GBL) Mixture Exemptions to Third Reading

California lawmakers are advancing SB 1306, which would add Section 11112 to the Health and Safety Code to exempt defined low-concentration gamma-butyrolactone mixtures from existing state precursor permitting, reporting, and billing requirements. If enacted, this alignment with federal exemptions would ease compliance burdens for chemical suppliers and semiconductor manufacturers using GBL mixtures in California while leaving federal Controlled Substances Act controls on higher-risk formulations in place.

1 May 2026, 17:57leginfo.legislature.ca.govUnited States

EU Delegated Regulation 2026/314 Adds Nine Drug Precursors To Category 1 Lists

The EU has now published Delegated Regulation (EU) 2026/314 in the Official Journal, formally adding nine synthetic cathinone and amphetamine precursors to the Category 1 EU drug precursor lists with effect from September 2026. Chemical and pharmaceutical supply chains handling these intermediates must prepare for full Category 1 licensing, authorisation, and monitoring obligations for intra-EU movements and import/export trade, significantly tightening diversion-risk controls.

1 May 2026, 13:40eur-lex.europa.euEuropean Union

Iowa Enacts HF 2202 Adding Synthetic Opioids And Precursors To Schedule I

Iowa has enacted HF 2202 to immediately add a range of new synthetic opioids, fentanyl analogues, and stimulants to its schedule I controlled substances and precursor lists, with an effective date of 16 April 2026. This significantly expands state-level criminal and reporting exposure for chemical suppliers, distributors, and healthcare operators handling these molecules, requiring rapid review of inventories, contracts, and compliance controls for any activity touching Iowa.

23 Apr 2026, 09:32legis.iowa.govUnited States

California Senate Public Safety Committee Advances SB 1306 on Gamma-Butyrolactone Mixture Exemptions

On 14 April 2026, a key California Senate committee advanced SB 1306, a bill to exempt certain low-concentration gamma-butyrolactone (GBL) mixtures from state precursor reporting and permitting requirements. If enacted, semiconductor and other industrial users could see reduced compliance burden for qualifying GBL mixtures while higher-risk formulations and federal controlled-substance obligations remain unaffected.

21 Apr 2026, 13:26leginfo.legislature.ca.govUnited States

Estonia Updates Narcotic and Psychotropic Substances and Precursors Act Effective 01 April 2026

Estonia has published an updated consolidated Narcotic and Psychotropic Substances and Their Precursors Act (NPALS), with the latest amendments entering into force on 01 April 2026. The changes mainly refine governance of narcotic-treatment register data and research ethics while leaving core licensing and reporting duties for narcotic drugs and precursors intact, so operators should confirm their permits and processes remain aligned with the current framework.

15 Apr 2026, 15:46riigiteataja.eeEstonia

US DEA Finalises List I Designation of P2P Methyl Glycidic Acid and Its Esters

The US DEA has finalized the designation of P2P methyl glycidic acid and its esters as List I chemicals, effective May 4, 2026. Operators must secure federal registrations and implement rigorous supply chain controls, as the zero-concentration threshold subjects all mixtures to strict oversight.

6 Apr 2026, 16:07federalregister.govUnited States

EU Council Working Party on Customs Union To Examine Drug Precursors Monitoring And Control Regulation Proposal

EU Council negotiations on the recast Drug Precursors Monitoring and Control Regulation are entering a detailed technical review phase in April 2026. This signals a move toward a more integrated and potentially stricter oversight framework for precursor chemicals, requiring businesses to prepare for updated compliance and reporting obligations across the supply chain.

2 Apr 2026, 09:23data.consilium.europa.euEuropean Union

Latvian Saeima Adopts Second Reading Of Pharmacy Law Amendments And Sets Third-Reading Deadline

Latvia has advanced amendments to its Pharmacy Law through the second reading, signaling imminent changes to the national pharmaceutical framework. Businesses should prepare for revised operational requirements governing the distribution of medicines and the management of drug precursors.

2 Apr 2026, 07:55titania.saeima.lvLatvia

US DEA Invites Comment on SpecGx LLC Bulk Manufacturer Registration for Schedule I and II Controlled Substances

The US DEA has opened a comment period on an application by SpecGx LLC to register as a bulk manufacturer for a wide range of Schedule I and II controlled substances. This move signals potential shifts in domestic supply chains and quota allocations for highly regulated substances, impacting competitive positioning and market access for existing manufacturers.

27 Mar 2026, 18:17govinfo.govUnited States

Honduras ARSA Updates Controlled Substances And Precursors List And Strengthens Control Regime

Honduras has updated its list of controlled substances and introduced new import restrictions for specialized manufacturing equipment effective April 2026. Businesses must audit chemical concentrations against new thresholds and update licensing to ensure continued market access and regulatory compliance.

27 Mar 2026, 17:14arsateca.arsa.hnHonduras

Argentina Adopts Decree 128/2026 Expanding Chemical Precursor Controls

Argentina expanded its chemical precursor control regime by adding 56 substances to the National Register, effective March 2026. Companies must immediately secure registration for newly listed industrial solvents and reagents to maintain market access and ensure trade compliance.

26 Mar 2026, 12:12boletinoficial.gob.arArgentina

US Congress Introduces H.R. 8005 To Amend Controlled Substances Act For Fentanyl And Counterfeit Substances

US House Bill H.R. 8005 was introduced in March 2026 to amend the Controlled Substances Act, targeting fentanyl, its analogues, and counterfeit substances. This proposal signals a likely tightening of federal oversight and enforcement, requiring manufacturers and distributors of high-risk substances to review supply chain integrity and compliance controls.

24 Mar 2026, 13:23congress.govUnited States

US DEA Updates Exempt Chemical Preparations Under the Controlled Substances Act

The US DEA has finalized status updates for hundreds of chemical preparations, granting or denying exemptions from Controlled Substances Act requirements. Businesses should audit product portfolios against the updated lists to confirm which preparations benefit from reduced regulatory burdens and which require full DEA compliance.

21 Mar 2026, 19:13govinfo.govUnited States

UN Commission on Narcotic Drugs Issues Draft Report Addendum on Synthetic Drugs and Access to Controlled Medicines (CND 69th Session)

The UN Commission on Narcotic Drugs has identified nitazenes, orphines, and designer precursors as priority targets for future international scheduling and control. Manufacturers should anticipate tighter global restrictions on these synthetic substance classes and increased monitoring of non-scheduled chemical precursors in supply chains.

14 Mar 2026, 15:21documents.un.orgGlobal

UN CND Circulates Revised Draft Resolution on Early Warning for New Synthetic Drugs and Precursors

The UN Commission on Narcotic Drugs is advancing a resolution to strengthen global early-warning systems for new synthetic drugs and chemical precursors. This signals an acceleration in international scheduling efforts, requiring businesses to monitor emerging precursor controls that could impact chemical supply chains.

14 Mar 2026, 08:23unodc.orgGlobal

US DEA Seeks Comment on Purisys, LLC Import Registration for Schedule I and II Controlled Substances

The US DEA is considering an application from Purisys, LLC to import various Schedule I and II controlled substances for pharmaceutical manufacturing, with comments due by April 13, 2026. This development signals potential shifts in the domestic supply chain for controlled precursors and APIs, allowing industry stakeholders to contest or support expanded import capacity.

13 Mar 2026, 13:25federalregister.govUnited States